BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26443528)

  • 1. The Neutrophil-to-Lymphocyte Ratio Predicts Malignant Potential in Intraductal Papillary Mucinous Neoplasms.
    Arima K; Okabe H; Hashimoto D; Chikamoto A; Kuroki H; Taki K; Kaida T; Higashi T; Nitta H; Komohara Y; Beppu T; Takeya M; Baba H
    J Gastrointest Surg; 2015 Dec; 19(12):2171-7. PubMed ID: 26443528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil-to-lymphocyte ratio and mural nodule height as predictive factors for malignant intraductal papillary mucinous neoplasms.
    Watanabe Y; Niina Y; Nishihara K; Okayama T; Tamiya S; Nakano T
    Acta Chir Belg; 2018 Aug; 118(4):239-245. PubMed ID: 29334845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
    Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
    Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive, mixed-type intraductal papillary mucinous neoplasm: superior prognosis compared to invasive main-duct intraductal papillary mucinous neoplasm.
    Ceppa EP; Roch AM; Cioffi JL; Sharma N; Easler JJ; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    Surgery; 2015 Oct; 158(4):937-44; discussion 944-5. PubMed ID: 26173683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic role of the neutrophil-to-lymphocyte ratio in predicting pancreatic ductal adenocarcinoma in patients with pancreatic diseases.
    Arima K; Okabe H; Hashimoto D; Chikamoto A; Tsuji A; Yamamura K; Kitano Y; Inoue R; Kaida T; Higashi T; Taki K; Imai K; Komohara Y; Beppu T; Takeya M; Baba H
    Int J Clin Oncol; 2016 Oct; 21(5):940-945. PubMed ID: 27023215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-to-lymphocyte Ratio is a Predictive Marker for Invasive Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Gemenetzis G; Bagante F; Griffin JF; Rezaee N; Javed AA; Manos LL; Lennon AM; Wood LD; Hruban RH; Zheng L; Zaheer A; Fishman EK; Ahuja N; Cameron JL; Weiss MJ; He J; Wolfgang CL
    Ann Surg; 2017 Aug; 266(2):339-345. PubMed ID: 27631774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Associated With Invasive Intraductal Papillary Mucinous Carcinoma of the Pancreas.
    Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yanagisawa A; Yamaue H
    JAMA Surg; 2017 Mar; 152(3):e165054. PubMed ID: 28122068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative evaluation of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas: clinical, radiological, and pathological analysis of 123 cases.
    Nara S; Onaya H; Hiraoka N; Shimada K; Sano T; Sakamoto Y; Esaki M; Kosuge T
    Pancreas; 2009 Jan; 38(1):8-16. PubMed ID: 18665010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimally invasive intraductal papillary-mucinous carcinoma of the pancreas: clinicopathologic study of 104 intraductal papillary-mucinous neoplasms.
    Nara S; Shimada K; Kosuge T; Kanai Y; Hiraoka N
    Am J Surg Pathol; 2008 Feb; 32(2):243-55. PubMed ID: 18223327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mural nodule in branch duct-type intraductal papillary mucinous neoplasms of the pancreas is a marker of malignant transformation and indication for surgery.
    Akita H; Takeda Y; Hoshino H; Wada H; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Mori M; Doki Y; Nagano H
    Am J Surg; 2011 Aug; 202(2):214-9. PubMed ID: 21376305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The natural history of main duct-involved, mixed-type intraductal papillary mucinous neoplasm: parameters predictive of progression.
    Roch AM; Ceppa EP; Al-Haddad MA; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    Ann Surg; 2014 Oct; 260(4):680-8; discussion 688-90. PubMed ID: 25203885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
    Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
    J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonoperative management of main pancreatic duct-involved intraductal papillary mucinous neoplasm might be indicated in select patients.
    Roch AM; DeWitt JM; Al-Haddad MA; Schmidt CM; Ceppa EP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    J Am Coll Surg; 2014 Jul; 219(1):122-9. PubMed ID: 24862887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant potential and specific characteristics of pure main duct type intraductal papillary mucinous neoplasm.
    Fujita Y; Hirono S; Kawai M; Okada KI; Miyazawa M; Kitahata Y; Ueno M; Hayami S; Kobayashi R; Yanagisawa A; Yamaue H
    Eur J Surg Oncol; 2022 May; 48(5):1054-1061. PubMed ID: 34933794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
    Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K
    Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic Resection for Side-Branch Intraductal Papillary Mucinous Neoplasm (SB-IPMN): a Contemporary Single-Institution Experience.
    Dortch JD; Stauffer JA; Asbun HJ
    J Gastrointest Surg; 2015 Sep; 19(9):1603-9. PubMed ID: 26055134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of a Revised Management Strategy for Patients With Intraductal Papillary Mucinous Neoplasms Involving the Main Pancreatic Duct.
    Sugimoto M; Elliott IA; Nguyen AH; Kim S; Muthusamy VR; Watson R; Hines OJ; Dawson DW; Reber HA; Donahue TR
    JAMA Surg; 2017 Jan; 152(1):e163349. PubMed ID: 27829085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and Prognostic Impact of Neutrophil-to-Lymphocyte Ratio for Intraductal Papillary Mucinous Neoplasms of the Pancreas With High-Grade Dysplasia and Associated Invasive Carcinoma.
    Hata T; Mizuma M; Motoi F; Ishida M; Morikawa T; Takadate T; Nakagawa K; Hayashi H; Kanno A; Masamune A; Kamei T; Furukawa T; Naitoh T; Unno M
    Pancreas; 2019 Jan; 48(1):99-106. PubMed ID: 30540681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraductal oncocytic papillary neoplasm of the pancreas: clinical and radiological features compared to those of intraductal papillary mucinous neoplasm.
    Nakaya M; Nakai Y; Takahashi M; Fukukura Y; Sato K; Kameda A; Tashiro Y; Kageyama S; Sofue K; Nakano T; Yoshimitsu K; Marugami N; Takeyama N; Tanaka M; Hasegawa K; Watadani T
    Abdom Radiol (NY); 2023 Aug; 48(8):2483-2493. PubMed ID: 37358603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas.
    Fritz S; Hackert T; Hinz U; Hartwig W; Büchler MW; Werner J
    Br J Surg; 2011 Jan; 98(1):104-10. PubMed ID: 20949535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.